CAMP4 Therapeutics Corporation (CAMP) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $343.32M; Retained Earnings (Accumulated Deficit)USD $-344.02M; Stockholders' Equity Attributable to ParentUSD $-693.00K.
- 2026-03-31: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $341.38M; Retained Earnings (Accumulated Deficit)USD $-310.49M; Stockholders' Equity Attributable to ParentUSD $30.90M.
- 2025-12-31: Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $339.85M; Retained Earnings (Accumulated Deficit)USD $-292.16M; Stockholders' Equity Attributable to ParentUSD $47.70M.
- 2025-09-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in CapitalUSD $310.53M; Retained Earnings (Accumulated Deficit)USD $-251.87M; Stockholders' Equity Attributable to ParentUSD $58.67M.
CAMP4 Therapeutics Corporation Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.00K | $343.32M | $-344.02M | $-693.00K | (m) | 3 month · $1.93M | (m) |
| 2026-03-31 | $6.00K | $341.38M | $-310.49M | $30.90M | (m) | 3 month · $1.47M | (m) |
| 2025-12-31 | $6.00K | $339.85M | $-292.16M | $47.70M | (m) | 12 month · $4.00M | 12 month · $3.60M |
| 2025-09-30 | $5.00K | $310.53M | $-251.87M | $58.67M | (m) | 3 month · $984.00K | 3 month · $3.60M |
| 2025-06-30 | $2.00K | $276.76M | $-236.77M | $39.99M | (m) | 3 month · $1.00M | (m) |
| 2025-03-31 | $2.00K | $275.76M | $-224.19M | $51.57M | (m) | 3 month · $861.00K | (m) |
| 2024-12-31 | $2.00K | $274.89M | $-211.75M | $63.14M | 12 month · $9.73M | 12 month · $4.03M | (m) |
| 2024-09-30 | $2.00K | $39.50M | $-198.47M | $-158.97M | (m) | 3 month · $1.59M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $-147.11M | (m) | 3 month · $786.00K | (m) |
| 2024-03-31 | (m) | (m) | (m) | $-135.33M | (m) | 3 month · $856.00K | (m) |
| 2023-12-31 | $1.00K | $36.23M | $-159.96M | $-123.73M | (m) | 12 month · $2.91M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $-111.55M | (m) | 3 month · $722.00K | (m) |
| 2023-06-30 | (m) | (m) | (m) | $-100.58M | (m) | 3 month · $786.00K | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-89.27M | (m) | 3 month · $763.00K | (m) |
| 2022-12-31 | (m) | (m) | (m) | $-77.53M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |